Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
13
RVNC Quote, Financials, Valuation and Earnings
Last price:
$3.08
Seasonality move
:
-2.77%
Day range:
$3.07 - $3.09
52-week range:
$2.30 - $9.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.16x
P/B ratio:
--
Volume:
3.5M
Avg. volume:
3.6M
1-year change:
-59.37%
Market cap:
$323.1M
Revenue:
$234M
EPS (TTM):
-$1.94
Analysts' Opinion
-
Consensus RatingRevance Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.64, Revance Therapeutics has an estimated upside of 147.96% from its current price of $3.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 2.6% downside risk from its current price of $3.08.
Fair Value
-
According to the consensus of 8 analysts, Revance Therapeutics has 147.96% upside to fair value with a price target of $7.64 per share.
RVNC vs. S&P 500
-
Over the past 5 trading days, Revance Therapeutics has overperformed the S&P 500 by 2.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Revance Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Revance Therapeutics has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Revance Therapeutics reported revenues of $59.9M.
Earnings Growth
-
Revance Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Revance Therapeutics reported earnings per share of -$0.37.
Enterprise value:
570.2M
EV / Invested capital:
2.13x
Price / LTM sales:
1.16x
EV / EBIT:
--
EV / Revenue:
2.22x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$179.3M
Return On Assets:
-37.25%
Net Income Margin (TTM):
-71.78%
Return On Equity:
--
Return On Invested Capital:
-61.49%
Operating Margin:
-53.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $108.6M | $204.2M | $256.9M | $54.1M | $59.9M | |
| Gross Profit | $72.6M | $133.8M | $179.3M | $37.3M | $42.2M | |
| Operating Income | -$259.2M | -$215.2M | -$195.3M | -$37.6M | -$32.3M | |
| EBITDA | -$232.4M | -$243.4M | -$268.9M | -$31.9M | -$28.6M | |
| Diluted EPS | -$3.92 | -$4.99 | -$1.94 | -$1.63 | -$0.37 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $450.1M | $293.9M | $415.6M | $388.5M | $329.7M | |
| Total Assets | $712.1M | $581.8M | $711.6M | $532.5M | $461.6M | |
| Current Liabilities | $63.7M | $65.9M | $74.7M | $82.2M | $80M | |
| Total Liabilities | $339.3M | $461.7M | $565.9M | $638.7M | $624.6M | |
| Total Equity | $372.9M | $120.2M | $145.7M | -$106.2M | -$163M | |
| Total Debt | $177.4M | $280.3M | $378.9M | $428.4M | $431.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$208M | -$204M | -$190.9M | -$51M | -$41.1M | |
| Cash From Investing | -$152.1M | $148.3M | -$12.9M | $51.6M | $23.3M | |
| Cash From Financing | $338.3M | $132M | $81.7M | $37.5M | -$6.1M | |
| Free Cash Flow | -$214.3M | -$210.4M | -$194.9M | -$55.5M | -$41.2M | |
RVNC
Sector
Market Cap
$323.1M
$43.9M
Price % of 52-Week High
31.61%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-19.8%
-0.74%
1-Year Price Total Return
-59.37%
-29.11%
Beta (5-Year)
0.815
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.07
200-day SMA
Sell
Level
$4.37
Bollinger Bands (100)
Sell
Level
3.74 - 6.28
Chaikin Money Flow
Buy
Level
48.2M
20-day SMA
Sell
Level
$3.46
Relative Strength Index (RSI14)
Sell
Level
33.10
ADX Line
Buy
Level
13.78
Williams %R
Buy
Level
-93.9655
50-day SMA
Sell
Level
$4.37
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-180M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.3289)
Sell
CA Score
(Annual)
Level (-5.7774)
Buy
Beneish M-Score
(Annual)
Level (-2.641)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.5734)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Stock Forecast FAQ
In the current month, RVNC has received 1 Buy ratings 7 Hold ratings, and 0 Sell ratings. The RVNC average analyst price target in the past 3 months is $7.64.
-
Where Will Revance Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Revance Therapeutics share price will rise to $7.64 per share over the next 12 months.
-
What Do Analysts Say About Revance Therapeutics?
Analysts are divided on their view about Revance Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Revance Therapeutics is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Revance Therapeutics's Price Target?
The price target for Revance Therapeutics over the next 1-year time period is forecast to be $7.64 according to 8 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is RVNC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Revance Therapeutics is a Hold. 7 of 8 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RVNC?
You can purchase shares of Revance Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Revance Therapeutics shares.
-
What Is The Revance Therapeutics Share Price Today?
Revance Therapeutics was last trading at $3.08 per share. This represents the most recent stock quote for Revance Therapeutics. Yesterday, Revance Therapeutics closed at $3.08 per share.
-
How To Buy Revance Therapeutics Stock Online?
In order to purchase Revance Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 0.02% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.7% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.65% over the past day.
